---
title: Stereotactic Radiation to Decrease Pancreatic Secretions
nct_id: NCT01656486
overall_status: COMPLETED
phase: NA
sponsor: Wake Forest University Health Sciences
study_type: INTERVENTIONAL
primary_condition: Pancreatic Fistulae
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01656486.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01656486"
ct_last_update_post_date: 2022-06-10
last_seen_at: "2026-05-12T06:18:43.113Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Stereotactic Radiation to Decrease Pancreatic Secretions

**Official Title:** Utilization of Stereotactic Radiation in Patients With Pancreatic Fistula to Decrease Pancreatic Secretions

**NCT ID:** [NCT01656486](https://clinicaltrials.gov/study/NCT01656486)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 1
- **Lead Sponsor:** Wake Forest University Health Sciences
- **Conditions:** Pancreatic Fistulae
- **Start Date:** 2012-07
- **Completion Date:** 2012-11
- **CT.gov Last Update:** 2022-06-10

## Brief Summary

Patients that have undergone pre-operative radiation for pancreatic carcinoma, that upon pathologic examination of the normal portion of the pancreatic gland that was in the radiation field showed acute and chronic changes in the pancreatic cells. The hypothesis for utilizing stereotactic radiation on pancreatic fistulae is that the treatment will decrease pancreatic secretions, thus decreasing autodigestion.

## Detailed Description

Stereotactic radiation for cancer has been utilized to successfully treat the head of the pancreas, which is generally a well-tolerated procedure with minimal complications. Upon further investigation under the microscope, after resection during a complex Whipple operation, it is noted that particularly the exocrine glandular tissue atrophied substantially. Based on this information, the hypothesis for utilizing stereotactic radiation on the remaining pancreas is production of a fibrosis of the pancreas and a decrease in the production of exocrine portion of the gland. The use of stereotactic radiation will be performed on individuals that are non-surgical candidates.

## Eligibility

- **Minimum age:** 18 Years
- **Maximum age:** 70 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Pancreatic fistula
* Non-surgical candidate

Exclusion Criteria:

* Surgical candidate
```

## Arms

- **Stereotactic Radiation** (EXPERIMENTAL) — Treatment of pancreas with 30 Gy of radiation given in 5 fractions of 6 Gy each with stereotactic radiosurgery.

## Interventions

- **Stereotactic Radiation** (RADIATION) — Treatment of pancreas with 30 Gy of radiation given in 5 fractions of 6 Gy each with stereotactic radiosurgery that could produce a fibrosis of the pancreas and a decrease in the production of exocrine portion of the gland.

## Primary Outcomes

- **Decreased Secretions** _(time frame: 1 year)_ — Measurement of pancreatic panel, decreased Pancreatic Secretions

## Locations (1)

- Carolinas Medical Center, Charlotte, North Carolina, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.maxAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.carolinas medical center|charlotte|north carolina|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01656486.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01656486*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*